PrEP Topics Examined at CROI 2014
Among the many issues being discussed by the scientists, providers, and advocates gathered at the 2014 Conference on Retroviruses and Opportunistic Infections (CROI) Exit Disclaimer in Boston this week is pre-exposure prophylaxis (PrEP) for HIV. In a number of clinical trials, daily oral PrEP has been proven to be an effective biomedical intervention for reducing the risk of HIV acquisition among adult men and women at very high risk for HIV infection through sex or injecting drug use. While studies have demonstrated the efficacy of PrEP and the Food and Drug Administration (FDA) has approved the use of Truvada® as PrEP, questions remain regarding how it can best be deployed to prevent HIV transmission in real world settings in the U.S. and elsewhere around the world.
Researchers are sharing their findings in various sessions across the conference, examining issues ranging from interest in and acceptability of PrEP among various populations, to factors that influence uptake and adherence, and strategies for deploying PrEP in the U.S. and in resource-limited settings in other parts of the world.
Click here to read full blog